Schott Pharma , a leading provider of drug containment solutions, has inaugurated a state-of-the-art glass manufacturing facility in Jagodina, Serbia, marking a significant investment in its European operations and bolstering its competitiveness within the region.
This double-digit million euro investment will generate approximately 180 jobs by the end of 2025, contributing to the local economy and solidifying Schott Pharma’s commitment to long-term growth in Europe.
The impressive speed of the project, with groundbreaking occurring in December 2023 and completion within just 1.5 years, underscores Schott Pharma’s efficiency and strategic focus. The facility will specialize in the production of glass ampoules, crucial containers for injectable medications such as analgesics, anti-inflammatories, and anaesthetics, further securing the supply chain for these essential pharmaceuticals.
This strategic expansion comes at a critical time for the pharmaceutical industry. As Schott Pharma CEO Andreas Reisse stated, “At a time when global tariffs and duties are rising and other European-based glass ampoule manufacturers are closing their doors, we can offer our regional customers a clear long-term perspective on how to secure their local supply chain.” This highlights the company’s commitment to providing reliable and locally sourced solutions for its European clientele.
Given that over 40% of the world’s commercial injectable drugs are stored in glass ampoules, the new facility plays a vital role in ensuring the safe and efficient delivery of medications to patients. Schott Pharma’s ampoules, manufactured from Type I borosilicate glass, are available in a wide range of options, including clear and amber glass, various shapes (B, C, D), and different breakage systems (one point cut, scoring, colour break). The portfolio encompasses over a thousand different articles, all manufactured under current Good Manufacturing Practices (cGMP).
Beyond the breadth of its product offerings, Schott Pharma emphasizes the quality and consistency of its ampoules. The facility is equipped with modern manufacturing technology and stringent inspection systems to guarantee the highest quality standards. This focus on uniform dimensions and high cosmetic quality ensures seamless compatibility with automated filling lines, minimizing downtime and reducing waste for pharmaceutical manufacturers. This commitment to precision and reliability helps pharmaceutical companies optimize efficiency, achieve product integrity, and ultimately, realize long-term cost savings.
The opening of the Jagodina facility signifies a strategic move by Schott Pharma to strengthen its position as a leading supplier of drug containment solutions in Europe. By investing in local production and focusing on quality and innovation, Schott Pharma is well-positioned to meet the evolving needs of the pharmaceutical industry and contribute to the safe and effective delivery of medications to patients worldwide.
Source: Schott Pharma with additional information added by GlassBalkan
